Page 62 - Read Online

Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43 Page 23 of 23

PubMed
120. Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol 2020;21:1152-9. DOI
PubMed
121. Angelini C, Bovo G, Muselli P, et al. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
Hepatogastroenterology 2006;53:141-4. PubMed
122. Caprotti R, Brivio F, Fumagalli L, et al. Free-from-progression period and overall short preoperative immunotherapy with IL-2
increases the survival of pancreatic cancer patients treated with macroscopically radical surgery. Anticancer Res 2008;28:1951-4.
PubMed
123. Amin S, Baine M, Meza J, Lin C. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer
patients: a retrospective analysis. BMC Cancer 2020;20:538. DOI PubMed PMC
124. Byrne KT, Betts CB, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor
microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res 2021;27:4574-86. DOI PubMed PMC
125. Hilmi M, Mitry E, Turpin A, et al. A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in
combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal
adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY. JCO 2022;40:4148-
4148. DOI